Demographic data | Total n=73 |
Median (range) age (years) | 76 (70–88) |
Blood pressure (mm Hg) | n=70 |
Mean systolic blood pressure | 133 |
Mean diastolic blood pressure | 71 |
Urine analyses (protein) in patients | n=46 |
0 (absent) | 31 (67%) |
+1 (trace) | 12 (26%) |
+2 (positive) | 2 (4%) |
+3/+4 (strong positive) | 1 (2%) |
CA125 measurement (U/mL) | n=62 |
Median | 338 |
Patients above upper normal limit* | 52 (84%) |
Chemotherapy before bevacizumab | |
Yes | 48 (66%) |
No | 25 (34%) |
n=48 | |
Median time from first chemotherapy to bevacizumab administration (days) | 21 |
Carboplatin and paclitaxel | 47 (64%) |
Carboplatin only | 1 (1%) |
Median initial dose of carboplatin, target AUC (IQR) | 4 (2.7–6) |
Initial frequency of carboplatin | |
Three weekly | 25 (52%) |
Weekly | 15 (31%) |
Other | 8 (17%) |
Median initial dose of paclitaxel, mg/m2 (IQR) | 96 (60–175) |
Initial frequency of paclitaxel | |
Three weekly | 17 (36%) |
Weekly | 22 (47%) |
Other | 8 (17%) |
Chemotherapy in combination with bevacizumab | |
Carboplatin and paclitaxel | 70 (96%) |
Other | 3 (4%) |
Comorbidities in more than 20% of patients | n=73 |
Hypertension | 40 (55%) |
Hypercholesterolemia | 19 (26%) |
Constipation | 16 (22%) |
Fatigue | 15 (21%) |
Status of ovarian cancer | n=72 |
Median (range) time since initial diagnosis (months) | 1 (0.6–2.9) |
Histology | |
Serous carcinoma | 36 (50%) |
Adenocarcinoma† | 21 (29%) |
Serous carcinoma+adenocarcinoma† | 5 (7%) |
Endometrioid adenocarcinoma† | 1 (1%) |
Other | 8 (11%) |
Unknown | 1 (1%) |
Geriatric assessment | |
ECOG | n=69 |
0 | 27 (39) |
1 | 30 (44) |
2 | 6 (9) |
3 | 6 (9) |
Geriatric risk profile questionnaire | n=69 |
Median score (IQR; ≥1 indicates geriatric risk) | 1 (1–2) |
Geriatric eight health status screening tool | n=69 |
Median score (IQR;≤14 is considered abnormal) | 11 (9–13) |
Pain visual analog scale | n=69 |
Median score (IQR; >0 to 3 is indicative of mild pain) | 1 (0–4) |
Activities of daily living | n=69 |
Median score (IQR; ≥7 is indicative of dependency) | 6 (6–7) |
Instrumental activities of daily living | n=69 |
Median score (IQR; <8 is indicative of dependency) | 7 (5–8) |
Falls history | |
Question 1 (fall history) | n=65 |
Yes (%) | 24 (37) |
Question 2 (fall-related injury) | n=56 |
Yes (%) | 22 (39) |
Mobility-tiredness test | n=68 |
Median score (IQR; ≥3 is indicative of tiredness) | 5 (3–6) |
Mini-mental state examination | n=69 |
Median score (IQR; ≥24 is indicative of normal cognition) | 28 (27–29) |
15-item geriatric depression scale | n=69 |
Median score (IQR; <5 is indicative of no depression risk) | 3 (2–5) |
Mini-nutritional assessment (total score) | n=68 |
Median score (IQR;17 to ≤23 is indicative of risk for malnutrition) | 22 (20–26) |
Charlson comorbidity index | n=66 |
Median score (IQR) | 1 (0–2) |
*Upper normal limit (out of normal range was assessed by the investigator according to local laboratory normal ranges; usually, a value <35 U/mL is considered normal).
†Not otherwise specified.
AUC, AUC: area under the curve; ECOG, Eastern Cooperative Oncology Group.